Keyphrases
Accelerated Approval
22%
Adverse Events
5%
Antineoplastic Agents
5%
BRAF V600E mutation
5%
BRAFV600
11%
Cancer Clinical Trials
13%
Clinical Drug Trials
5%
Clinical Trial Data
5%
Clinical Trial Registry
37%
Clinical Trials
66%
Combination Therapy
5%
Consolidated Standards of Reporting Trials (CONSORT)
16%
Core Outcome Set
33%
Dabrafenib
33%
Dabrafenib Plus Trametinib
5%
Data Extraction
9%
Data Reporting
8%
Data Screening
9%
Drug Development
33%
Equator
8%
EQUATOR Network
12%
FDA-approved Drugs
5%
Health Journals
33%
Improved Outcomes
9%
Kinase Inhibitor
5%
Malignancy
11%
Melanoma
5%
Mental Health
33%
Off-label Indications
5%
Ovarian Cancer
33%
Overall Survival Progression-free Survival
8%
Patient Benefit
33%
Patient Outcomes
37%
Patient Risk
33%
Patient-reported Outcomes
8%
PRISMA
8%
Psychiatry
33%
Psychiatry Journals
8%
PubMed
5%
Reporting Guidelines
33%
Response Evaluation Criteria in Solid Tumors (RECIST)
5%
Risk Outcomes
33%
Risk-benefit
33%
Sectional Analysis
33%
Standardized Outcomes
8%
Thyroid Cancer
5%
Trametinib
33%
Treatment Methods
5%
Trial Registration
8%
Yield Quality
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Cross Sectional Study
33%
Dabrafenib
33%
Drug Development
33%
Female Genital Tract Cancer
5%
Ovary Cancer
33%
Overall Survival
11%
Progression Free Survival
11%
Randomized Controlled Trial
6%
Trametinib
33%
